ERBB2 and neoplasm: Pretreatment with chemotherapy can enhance the anti-tumor effect of anti-Her2 and anti-CD47 therapy, whereas chemotherapy applied following anti-Her2 or anti-CD47 treatment abolishes the tumor regression induced by either single treatment and even destroyed the tumor-specific T-cell memory responses (Liu et al.2015; Park et al.2010).